Get the Stockscreener App
0.7592
1.36%
0.0102
After Hours:
.78
0.0208
+2.74%
Rani Therapeutics Holdings Inc stock is traded at $0.7592, with a volume of 379.40K.
It is up +1.36% in the last 24 hours and down -14.79% over the past month.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
See More
Previous Close:
$0.749
Open:
$0.755
24h Volume:
379.40K
Relative Volume:
0.50
Market Cap:
$87.63M
Revenue:
$3.17M
Net Income/Loss:
$-36.23M
P/E Ratio:
-1.8571
EPS:
-0.4088
Net Cash Flow:
$-17.11M
1W Performance:
-11.93%
1M Performance:
-14.79%
6M Performance:
-33.40%
1Y Performance:
+58.43%
1-Day Range:
$0.7306
$0.775
1-Week Range:
$0.7306
$0.8698
52-Week Range:
$0.4453
$3.87
Rani Therapeutics Holdings Inc Stock (RANI) Company Profile
Name
Rani Therapeutics Holdings Inc
Sector
Industry
Phone
(408) 457-3700
Address
2051 RINGWOOD AVENUE, SAN JOSE
Compare RANI vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RANI
Rani Therapeutics Holdings Inc
|
0.7592 | 87.63M | 3.17M | -36.23M | -17.11M | -0.4088 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rani Therapeutics Holdings Inc Stock (RANI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Lake Street | Buy |
| Aug-02-24 | Initiated | Oppenheimer | Outperform |
| Jun-14-24 | Initiated | Maxim Group | Buy |
| Jun-13-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Oct-11-22 | Initiated | UBS | Buy |
| Jul-27-22 | Initiated | H.C. Wainwright | Buy |
| Jun-13-22 | Initiated | Wedbush | Outperform |
View All
Rani Therapeutics Holdings Inc Stock (RANI) Latest News
Rani Therapeutics (RANI) Short Interest & Short Float | Updated Sep 2026 - MarketBeat
RANI Stock Price, Quote & Chart - ChartMill
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Definium Therapeutics (DFTX) and enGene Holdings (ENGN) - The Globe and Mail
Rani Therapeutics Holdings (RANI) Trades at $0.82, Holding a Narrow Sub-$1 RangeMerger Arbitrage - careplusvn.com
Rani Therapeutics at H.C. Wainwright: oral biologics gain traction By Investing.com - Investing.com UK
RANI: RaniPill's strong clinical data and major partnerships drive growth, with manufacturing and cash runway secured - tradingview.com
Rani Therapeutics (RANI) Institutional Ownership 2026 $RANI - MarketBeat
Rani Therapeutics Holdings, Inc. (RANI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Rani Therapeutics will appear in New York on Sept. 10 and 14 - Stock Titan
Rani Therapeutics to Participate in Upcoming September Conferences - GlobeNewswire
Rani Therapeutics Holdings Stock Price Forecast. Should You Buy RANI? - StockInvest.us
Rani Therapeutics Holdings Inc (RANI) Peer Comparison – Compare with Others - valueresearchonline.com
RANI Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost Discipline Amid Pre-Revenue Stage - careplusvn.com
Rani Therapeutics Holdings Inc (RANI) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Rani (RANI) Earnings Report: EPS Beats Its Estimate in Latest Trading; Trading Response: The Stock Gains 3.41% on the DayGuidance Accuracy Score - vinanet.vn
Rani (RANI) Trading: Finishes 3.41% Up at $0.88 in the Latest Session; Technical View: the Supplied Trading Band Runs From $0.84 to $0.92 in the Available RecordTWAP Entry - vinanet.vn
HC Wainwright Reaffirms "Buy" Rating for Rani Therapeutics (NASDAQ:RANI) - MarketBeat
H.C. Wainwright reiterates Rani Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Rani Therapeutics stock rating at buy - Investing.com
We're Hopeful That Rani Therapeutics Holdings (NASDAQ:RANI) Will Use Its Cash Wisely - webull.com
Chardan Capital Maintains Rani Therapeutics(RANI.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tues - Benzinga
Chardan Capital Initiates Coverage on Rani Therapeutics (NASDAQ:RANI) - MarketBeat
RANI Q1 2026 Earnings: Narrower Loss Beats Estimates; Shares Jump 9.5%Dividend Earnings Report - careplusvn.com
Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline - MarketBeat
Rani Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Rani Therapeutics (RANI) Edges Lower to $0.80 as Stock Tests Crucial Support ZonePercent Below MA - vinanet.vn
RA Capital details 11,530,414 Rani Therapeutics (RANI) shares under 9.99% cap - Stock Titan
Rani Therapeutics | 10-Q: Q2 2026 Earnings Report - Moomoo
Rani Therapeutics Holdings earnings beat by $0.01, revenue topped estimates - Investing.com Canada
8-K: Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Updatemoomoo - Moomoo
Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Rani Therapeutics Q2 Results: EPS beats estimate, sales up 85% - scanx.trade
Rani Therapeutics (RANI) boosts liquidity with $20M raise and Chugai revenue - Stock Titan
Rani Therapeutics reports Q2 2026: $1.7M contract revenue, $8.4M quarterly net loss, $53.4M cash - TradingView
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update - The Manila Times
Rani Therapeutics' Oral RT-114 Tops 150% Bioavailability - Stock Titan
Rani Therapeutics at Canaccord Genuity conference: oral biologics push By Investing.com - Investing.com Canada
RANI: Oral biologics platform shows strong clinical and business momentum, with funding secured into 2027 - TradingView
Rani Therapeutics (RANI) Edges Higher by 2.93% as Shares Approach Key $0.84 ResistanceVolume Oscillator - careplusvn.com
Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Rani Therapeutics CEO, CFO to Present, Hold 1x1 Meetings Aug. 12 - Stock Titan
Rani Therapeutics Holdings Inc (RANI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RANI Q2'26 Earnings: EPS estimate is (0.05) USD - TradingView
Rani Therapeutics appoints Michelle Gilson to board By Investing.com - Investing.com UK
Rani Therapeutics appoints Michelle Gilson to board - The Globe and Mail
Rani Therapeutics Holdings, Inc. (RANI) awards 247,200 stock options to director - Stock Titan
Rani Therapeutics Holdings, Inc. (RANI) details director option holding - Stock Titan
Rani Therapeutics files Form 3 for director Michelle Gilson - Bitget
Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair - Quiver Quantitative
Rani Therapeutics Holdings Inc Stock (RANI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):